Insulet Co. (NASDAQ:PODD) Shares Sold by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. lowered its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 39.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 155,500 shares of the medical instruments supplier's stock after selling 101,820 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 0.22% of Insulet worth $40,596,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in PODD. SBI Securities Co. Ltd. purchased a new position in shares of Insulet during the 4th quarter worth $36,000. SRS Capital Advisors Inc. lifted its position in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 56 shares during the last quarter. Friedenthal Financial purchased a new position in Insulet during the fourth quarter worth about $57,000. Assetmark Inc. increased its position in shares of Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after acquiring an additional 246 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Insulet by 117.3% in the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock valued at $72,000 after acquiring an additional 149 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Canaccord Genuity Group boosted their target price on Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Piper Sandler boosted their price objective on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Stifel Nicolaus raised their price target on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a research report on Friday, February 21st. Wells Fargo & Company increased their price objective on Insulet from $305.00 to $322.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Finally, Raymond James reiterated an "outperform" rating and issued a $328.00 target price (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat, Insulet presently has an average rating of "Moderate Buy" and an average price target of $292.06.

Insider Transactions at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now owns 3,231 shares of the company's stock, valued at $888,525. The trade was a 36.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.47% of the company's stock.

Insulet Stock Down 0.5 %

Shares of NASDAQ PODD traded down $1.19 during mid-day trading on Monday, reaching $259.52. The company had a trading volume of 765,964 shares, compared to its average volume of 713,994. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The stock has a market cap of $18.23 billion, a P/E ratio of 44.82, a PEG ratio of 3.62 and a beta of 1.30. The firm has a 50 day simple moving average of $260.21 and a two-hundred day simple moving average of $261.91. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million during the quarter, compared to analysts' expectations of $582.02 million. Sell-side analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.